Cancer vaccines for hepatocellular carcinoma: future directions

References

• 1 Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat. Rev. Gastroenterol. Hepatol. 10(1), 34–42 (2013).
  Medline CASGoogle Scholar
• 2 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr. Oncol. Rep. 14(3), 257–266 (2012).
  Medline CASGoogle Scholar
• 3 Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut 64(5), 842–848 (2015).
  Medline CASGoogle Scholar
• 4 Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM. Challenges in cancer vaccine development for hepatocellular carcinoma. J. Hepatol. 59(4), 897–903 (2013).
  Medline CASGoogle Scholar
• 5 den Brok MH, Sutmuller RP, van der Voort R et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 64(11), 4024–4029 (2004).
  Medline CASGoogle Scholar
• 6 Jansen MC, van HR, Schoots IG et al. Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. Surgery 147(5), 686–695 (2010).
  MedlineGoogle Scholar
• 7 Maiti R. Metronomic chemotherapy. J. Pharmacol. Pharmacother. 5(3), 186–192 (2014).
  Medline CASGoogle Scholar
• 8 Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin. Oncol. 39(3), 323–339 (2012).
  Medline CASGoogle Scholar
• 9 Ge Y, Domschke C, Stoiber N et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol. Immunother. 61(3), 353–362 (2012).
  Medline CASGoogle Scholar
• 10 Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11(18), 6713–6721 (2005).
  Medline CASGoogle Scholar
• 11 Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2), 205–214 (2015).
  Medline CASGoogle Scholar
• 12 Bertino G, Demma S, Ardiri A et al. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed. Res. Int. 731469 (2015).
  MedlineGoogle Scholar
• 13 El Ansary M, Mogawer S, Elhamid SA et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J. Cancer Res. Clin. Oncol. 139(1), 39–48 (2013).
  Medline CASGoogle Scholar
• 14 Singh-Jasuja H, Emmerich NP, Rammensee HG. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol. Immunother. 53(3), 187–195 (2004).
  Medline CASGoogle Scholar
• 15 Heidenreich R, Jasny E, Kowalczyk A et al. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int. J. Cancer 137, 372–384 (2015).
  Medline CASGoogle Scholar
• 16 Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 348(6230), 69–74 (2015).
  Medline CASGoogle Scholar
• 17 Castle JC, Kreiter S, Diekmann J et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72(5), 1081–1091 (2012).
  Medline CASGoogle Scholar
• 18 Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 339(6127), 1546–1558 (2013).
  Medline CASGoogle Scholar
• 19 Greten TF, Forner A, Korangy F et al. A Phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 10, 209 (2010).
  MedlineGoogle Scholar
• 20 Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int. J. Oncol. 46(1), 28–36 (2015).
  Medline CASGoogle Scholar